| 1 |
Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension |
|
| | Kai Man Xu, Ryan Cho, Toby Yiu Bong Chan | | | Clinical Ophthalmology. 2022; Volume 16: 2385 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Bimatoprost: a unique compound that in its nonhydrolyzed form is a prostamide and hydrolyzed form has prostaglandin receptor activity, for glaucoma and cosmetic indications |
|
| | E Randy Craven,Sultan A Alzuhairy | | | Expert Review of Ophthalmology. 2014; 9(3): 159 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Prostaglandin analogues in angle closure glaucoma |
|
| | Gupta, P., Mahesh, B.S., Gupta, H.L. | | | Indian Journal of Ophthalmology. 2011; 59(5): 411-412 | | | [Pubmed] [Google Scholar] | |
|
.png "Santen")
